Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

TransMedics Group Inc

Healthcare US TMDX

71.895USD
2.21(3.16%)

Last update at 2026-06-04T18:12:00Z

Day Range

69.7073.91
LowHigh

52 Week Range

36.42143.46
LowHigh

Fundamentals

  • Previous Close 69.69
  • Market Cap4705.42M
  • Volume559092
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA26.19M
  • Revenue TTM296.92M
  • Revenue Per Share TTM9.10
  • Gross Profit TTM 65.27M
  • Diluted EPS TTM-0.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -36.16500M -44.17900M -28.71600M -33.50700M -23.71500M
Minority interest - - - - -
Net income -36.23100M -44.21500M -28.74800M -33.54700M -23.75600M
Selling general administrative 51.69M 38.28M 24.19M 23.60M 12.31M
Selling and marketing expenses 18.21M - 0.93M - 1.02M
Gross profit 65.27M 21.16M 16.64M 13.86M 5.73M
Reconciled depreciation 3.48M 1.82M 1.58M 1.22M 0.77M
Ebit -31.43700M -39.42800M -26.38400M -29.60300M -20.45000M
Ebitda -32.43900M -40.30500M -24.73100M -28.81300M -19.68100M
Depreciation and amortization -1.00200M -0.87700M 1.65M 0.79M 0.77M
Non operating income net other - -0.87700M - - -
Operating income -31.43700M -39.42800M -26.38400M -29.60300M -20.23700M
Other operating expenses 124.90M 69.69M 52.02M 53.21M 33.25M
Interest expense 3.73M 3.87M 3.98M 4.35M 2.72M
Tax provision 0.07M 0.04M 0.03M 0.04M 0.04M
Interest income - - - - -
Net interest income -3.72600M -3.87400M -3.98500M -4.35300M -2.72000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.07M 0.04M 0.03M 0.04M 0.04M
Total revenue 93.46M 30.26M 25.64M 23.60M 13.02M
Total operating expenses 96.71M 60.59M 43.02M 43.47M 25.97M
Cost of revenue 28.19M 9.10M 9.00M 9.74M 7.28M
Total other income expense net -4.72800M -4.75100M -2.33200M -3.90400M -0.75800M
Discontinued operations - - - - -
Net income from continuing ops -36.23100M -44.21500M -28.71600M -33.54700M -23.75600M
Net income applicable to common shares -36.23100M -44.21500M -28.74800M -33.54700M -23.75600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 706.05M 277.15M 134.89M 152.03M 105.30M
Intangible assets 2.35M - - - -
Earning assets - - - - -
Other current assets 8.03M 2.90M 5.46M 2.33M 1.54M
Total liab 568.85M 89.77M 67.04M 48.13M 50.65M
Total stockholder equity 137.20M 187.38M 67.85M 103.89M 54.65M
Deferred long term liab - - - 1.60M -
Other current liab 38.22M 18.64M 16.34M 10.41M 8.70M
Common stock 641.11M 666.28M 510.49M 502.22M 424.13M
Capital stock 641.11M 666.28M 510.49M 502.22M 424.13M
Retained earnings -503.70500M -478.67700M -442.44600M -398.23100M -369.48300M
Other liab - - - 1.60M 0.39M
Good will 11.99M - - - -
Other assets - 0.50M 0.50M 0.51M 0.51M
Cash 394.81M 201.18M 25.58M 24.58M 20.09M
Cash and equivalents - - - - -
Total current liabilities 54.93M 23.66M 23.24M 11.88M 16.11M
Current deferred revenue 1.96M 0.24M 0.25M 0.26M 0.17M
Net debt 121.13M -133.62700M -16.97600M 10.08M 14.05M
Short term debt 2.04M 1.44M 8.60M - -
Short long term debt - - - - -
Short long term debt total 515.95M 67.56M 8.60M 34.66M 34.15M
Other stockholder equity - -0.22500M 68.04M -0.09500M -105.29900M
Property plant equipment - 24.35M 15.69M 4.75M 4.79M
Total current assets 510.65M 252.29M 118.70M 146.77M 100.00M
Long term investments - - - - -
Net tangible assets - 187.38M 67.85M 103.89M 54.65M
Short term investments - 0.00000M 66.87M 101.06M 60.60M
Net receivables 63.58M 27.61M 5.93M 6.86M 6.56M
Long term debt 506.20M 58.70M 35.20M 34.66M 34.15M
Inventory 44.23M 20.61M 14.86M 11.93M 11.22M
Accounts payable 12.72M 3.34M 6.65M 1.21M 7.25M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.19900M -0.22500M -0.18800M -0.09500M -0.00200M
Additional paid in capital - - - - -
Common stock total equity - - 510.49M 502.22M 424.13M
Preferred stock total equity - - - - -
Retained earnings total equity - - -442.44600M -398.23100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.50M 0.50M 0.51M 0.51M
Deferred long term asset charges - - - - -
Non current assets total 195.39M 24.85M 16.19M 5.26M 5.30M
Capital lease obligations 9.74M 8.86M 8.60M - -
Long term debt total - - 35.20M 34.66M 34.15M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 54.51M 32.79M -41.14300M -60.50100M 12.72M
Change to liabilities -3.27000M 9.96M -5.74200M 3.31M 0.23M
Total cashflows from investing activities 54.51M 29.27M -41.59800M -60.50100M 12.31M
Net borrowings 22.46M 22.46M 22.46M 22.46M 24.36M
Total cash from financing activities 167.93M 1.39M 75.55M 92.72M 22.06M
Change to operating activities 6.21M 1.96M 2.11M 2.35M 0.65M
Net income -36.23100M -44.21500M -28.74800M -33.54700M -23.75600M
Change in cash 175.60M 1.00M 4.49M -0.14900M 8.30M
Begin period cash flow 26.08M 25.08M 20.59M 20.74M 12.44M
End period cash flow 201.68M 26.08M 25.08M 20.59M 20.74M
Total cash from operating activities -45.81700M -28.86400M -30.26500M -32.28600M -25.98400M
Issuance of capital stock 139.85M 0.00000M 75.67M 97.37M 0.00000M
Depreciation 3.48M 1.82M 1.58M 1.22M 0.77M
Other cashflows from investing activities - - - -60.33600M 12.72M
Dividends paid - - -0.35700M - -
Change to inventory -8.02400M -4.89400M -1.74000M -4.12100M -2.69900M
Change to account receivables -21.67800M 0.84M -0.21800M -3.16600M -2.51300M
Sale purchase of stock 0.51M 0.42M 0.36M 0.20M 0.05M
Other cashflows from financing activities 63.61M 0.97M 2.13M -4.64400M 31.14M
Change to netincome 13.70M 7.81M 2.49M 1.67M 1.33M
Capital expenditures 11.91M 3.52M 0.46M 0.17M 0.42M
Change receivables - 0.84M - - -
Cash flows other operating - -1.53900M - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 1.80M - - -
Change in working capital -26.75900M 3.00M -5.58800M -1.62600M -4.32700M
Stock based compensation 10.32M 6.88M 2.41M 0.85M 0.14M
Other non cash items 3.37M 1.37M 0.51M 0.47M 0.18M
Free cash flow -57.72400M -32.38300M -30.72000M -32.45100M -26.40200M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
TMDX
TransMedics Group Inc		 2.21 3.16% 71.89 - 250.00 12.48 21.98 12.98 -407.2289
ABT
Abbott Laboratories		 2.58 2.97% 89.57 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 3.14 1.06% 298.14 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 3.30 4.23% 81.25 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.81 1.71% 48.51 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TransMedics Group Inc

200 Minuteman Road, Andover, MA, United States, 01810

Key Executives

Name Title Year Born
Dr. Waleed H. Hassanein M.D. Founder, Pres, MD, CEO & Director 1968
Mr. Stephen Gordon CFO. Treasurer & Sec. 1968
Dr. Tamer I. Khayal M.D. Chief Commercial Officer 1969
Ms. Miriam C. Provost Ph.D. VP of Global Regulatory Affairs NA
Ms. Laura Damme VP of Clinical Affairs NA
Mr. John F. Carey VP of Operations 1965
Mr. Mark Anderson Sr. Director of Technology Devel. NA
Ms. Susan Goodman VP of HR NA
Dr. Waleed H. Hassanein M.D. Founder, President, CEO & Director 1968
Mr. Stephen Gordon CFO, Treasurer & Secretary 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.